Impact of long-acting therapies on the global HIV epidemic. (15th December 2021)

• Record Type: Journal Article
• Authors: Chandiwana, Nomathemba C.; Serenata, Celicia M.; Owen, Andrew; Rannard, Steve; Pérez Casas, Carmen; Scott, Cherise; Hill, Andrew; Clayden, Polly; Flexner, Charles
• Is Part Of: AIDS. Volume 35:Supplement 2(2021)
• Publication Date: 2021-12-15
• Subjects: access and barriers -- long-acting antiretrovirals -- low-income and middle-income countries -- treatment optimization; AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome; AIDS (Disease); Periodicals; Periodicals; 616.9792005
• DOI: 10.1097/QAD.0000000000003102
• Languages: English
• ISSNs: 0269-9370

Abstract

Abstract : N/A: Long-acting antiretroviral drugs have emerged as exciting treatment and preexposure prophylaxis (PrEP) options for people with HIV and at risk of HIV. Long-acting regimens may improve dosing convenience, tolerability and cost compared with current daily-based oral therapy. They can also circumvent stigma associated with oral therapy for both treatment and PrEP, thereby improving adherence and outcomes. Yet, multiple challenges remain, many specific to low-income and middle-income countries (LMICs), where the epidemic is most concentrated and HIV prevention and treatment options are limited. To optimize the use of long-acting formulations, key outstanding questions must be addressed. Uncertain costing, scale-up manufacturing, complex delivery systems and implementation challenges are potential barriers when considering the scalability of long-acting ARVs for global use.